News Search Results

Displaying Results 251-275 of 635 "ophthalmology"

Jul 19, 2024, 10:15 ET Immunotherapy Drugs Market worth $580.6 billion by 2029 driven by Technological Advancements | MarketsandMarkets™

market is categorized by applications into cancer, autoimmune & inflammatory diseases, hematology, osteology, neurology, and other areas such as ophthalmology, dermatology, and cardiovascular diseases. In 2023, cancer emerged as the leading application area, capturing the largest market share. This is

More news about: MarketsandMarkets


Jul 18, 2024, 21:37 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE

("IOP"). Skye intends to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027."  On this news,

More news about: Pomerantz LLP


Jul 18, 2024, 17:02 ET Amniotic Membrane Market size is set to grow by USD 2.72 billion from 2024-2028, Extensive use of amniotic membrane transplantation in ophthalmic surgeries boost the market, Technavio

and anti-microbial capabilities, making it suitable for various medical applications. In hospitals, its uses span across ophthalmology, wound healing, and dermatology. In ophthalmology, it's utilized as a graft for promoting wound healing, reducing scarring, and treating ocular surface disorders. For wound

More news about: Technavio


Jul 17, 2024, 16:44 ET Bascom Palmer Eye Institute Ranked Nation's # 1 in Ophthalmology for 23rd time

Health System and the University of Miami Miller School of Medicine, has been ranked the nation's Best in Ophthalmology by U.S. News & World Report in its annual Best Hospitals survey. This comprehensive guide serves as a valuable resource for consumers

More news about: UNIVERSITY OF MIAMI - OTHER SCHOOLS


Jul 17, 2024, 10:01 ET AI-Based Medical Diagnostic Tools Market Set to Exceed USD 11.5 Billion by 2034: Global Surge in AI Start-up Funding Expands Diagnostic Systems Integration | TMR

etc.)By Application RadiologyCardiologyNeurologyOncologyOthers (Ophthalmology, Gynecology, etc.)By End User HospitalsDiagnostic LaboratoriesOthers (Ambulatory Surgical

More news about: Transparency Market Research


Jul 17, 2024, 08:03 ET Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling

technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

More news about: InMode Ltd.


Jul 16, 2024, 13:25 ET Contact and Intraocular Lens Market Expected to Reach US$ 22.9 Billion by 2034, with a 6.4% CAGR Growth | States Transparency Market Research, Inc.

cataract surgery equipment, refractive technology, and vitreoretinal surgery equipment.Carl Zeiss Meditec AG produces robotic equipment for ophthalmology, cataract operations, and spine-related treatments.Key Players Johnson & JohnsonAlcon

More news about: Transparency Market Research


Jul 16, 2024, 13:06 ET Corneal Transplant Market to Reach an Estimated US$ 805.8 Million by 2034 with a CAGR of 5.6% from 2024 to 2034 | Exclusive Report by Transparency Market Research Inc.

technologies supports high-quality surgical procedures, including corneal transplants.Substantial investments in research and development in ophthalmology and corneal transplant techniques lead to innovative treatments and improved surgical outcomes, boosting market growth.Asia

More news about: Transparency Market Research


Jul 16, 2024, 09:15 ET Jefferson Health Hospitals and Specialties Ranked Among the Nation's Best According to U.S. News & World Report

the United States. Thomas Jefferson University Hospitals was recognized as second in the nation for Ophthalmology (Wills Eye Hospital), and MossRehab, now Jefferson Moss-Magee Rehabilitation, ranked 8th in the country for Rehabilitation.

More news about: Jefferson


Jul 16, 2024, 08:02 ET Tampa General Rises to 2nd Highest-Ranked Hospital in the Sunshine State, According to U.S. News & World Report

Brooksville is recognized by U.S. News & World Report as being among the 2024-2025 Best Ambulatory Surgery Centers for Ophthalmology. Tampa General and the USF Health Morsani College of Medicine comprise one of the nation's leading academic health systems. TGH and USF Health

More news about: Tampa General Hospital


Jul 15, 2024, 11:00 ET Eluminex Biosciences Announces First Patient Dosed in the Phase 1b LOTUS Trial of the Novel Trispecific Fusion Antibody EB-105 in Diabetic Macular Edema (DME)

patients with DME. The LOTUS trial is a first-in-human, open-label, multicenter, single injection, dose-escalation study of EB-105, Eluminex's lead ophthalmology asset being conducted at four sites in the United States. EB-105 has been shown in preclinical studies to potently

More news about: Eluminex Biosciences


Jul 15, 2024, 10:25 ET Active Pharmaceutical Ingredients (API) Market to Surpass USD 351.81 Billion Valuation by 2031, High Demand for Effective Therapeutics and Drugs Driving Market Development | SkyQuest Technology

Communicable Diseases, Oncology, Cardiovascular Diseases, Orthopaedic, Cardiology, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, OthersEnd-UserPharmaceutical and Biotechnological Industry, Contact Research Organization, Contract Manufacturing

More news about: SkyQuest Technology


Jul 15, 2024, 07:00 ET HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

endocrine, circulatory, and urologic diseases for over 50 years. HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. One of its lead pipeline assets,

More news about: HanAll Biopharma


Jul 11, 2024, 08:30 ET InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024

technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

More news about: InMode LTD


Jul 10, 2024, 18:38 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE

("IOP"). Skye intends to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027."  On this news,

More news about: Pomerantz LLP


Jul 10, 2024, 10:01 ET Recombinant Coagulation Factors Market to Be Worth $26.29 Billion by 2031 - Exclusive Report by Meticulous Research®

Therapy Market by Type (Pure Platelet-rich Plasma, Platelet-rich Fibrin), Application (Orthopedics, Dermatology, Cosmetology, Rheumatology, Ophthalmology), End User (Hospitals and Clinics, Research Institutes) - Global Forecast to 2028

More news about: Meticulous Market Research Pvt. Ltd.


Jul 10, 2024, 07:00 ET Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Opsin (MCO) gene therapy platform will be featured in a presentation by Dr. Michael Singer, Clinical Professor of Ophthalmology at the University of Texas Health Science Center, at the 

More news about: Nanoscope Therapeutics


Jul 10, 2024, 06:42 ET Advancements in Health Screening: Empowering Early Detection and Prevention

  Key Interesting Facts About the global market for routine health screening: AI in Ophthalmology:Exceptional diagnostic capabilities in detecting retinal conditions, glaucoma, and other eye diseases.State-of-the-art

More news about: BCC Research LLC


Jul 08, 2024, 06:31 ET Star Health Insurance Partners with Himachal Pradesh State Cooperative Bank to Enhance Health Insurance Penetration in the State

plans to add 10 more locations in FY25. The top 5 sicknesses faced by people of HP are Gastroenterology, orthopaedics, obstetrics, urology and ophthalmology, based on claims in the state. The health insurance products which are most purchased by customers are Family Health Optima, Star Health Assure

More news about: Star Health and Allied Insurance


Jul 08, 2024, 05:00 ET DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Lp-PLA2 Inhibitor for DR and DME

923-931 (2005).3. Diabetes Care 35, 556-564 (2012).4. Ophthalmology 122, 1375-1394 (2015).5. Ophthalmology 117, 1064-1077 (2010).6. Semin. Immunopathol. 30, 65-84 (2008).7. Ophthalmology 122, 990-996 (2015).

More news about: DP Technology


Jul 05, 2024, 04:30 ET IASO Bio and Innovent Enhance Strategic Collaboration in Cell Therapy

biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology, and other major diseases, jointly announced the agreement on a series of cooperation, including IASO Bio's purchase from Innovent regarding its

More news about: IASO Bio


Jul 05, 2024, 04:30 ET Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy

that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, and IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing, and

More news about: Innovent Biologics


Jul 03, 2024, 13:00 ET MemorialCare Named Best Ambulatory Surgery Centers in U.S. News & World Report Inaugural Ratings

U.S. News & World Report rated nearly 5,000 surgery centers in four separate specialty areas: Colonoscopy & Endoscopy, Ophthalmology, Orthopedics & Spine, and Urology FOUNTAIN VALLEY, Calif.,

More news about: MemorialCare Medical Group


Jul 03, 2024, 08:00 ET Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies

Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space. Find out more about Beacon Therapeutics at beacontx.com. Contact:

More news about: Beacon Therapeutics


Jul 02, 2024, 08:30 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE

("IOP").  Skye intends to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027."  On this news,

More news about: Pomerantz LLP